Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response.

ABSTRACT:

Background

Novel direct-acting antiviral DAA combination therapies tremendously improved sustained virologic response (SVR) rates in patients with chronic HCV infection. SVR is typically accompanied by normalization of liver enzymes, however, hepatic inflammation, i.e. persistently elevated aminotransferase levels may persist despite HCV eradication. Aim: To investigate prevalence and risk factors for ongoing hepatic inflammation after SVR in two large patient cohorts.

Methods

This post-hoc analysis was based on prospectively collected demographic and clinical data from 834 patients with SVR after HCV treatment with either PegIFN- or DAA-based treatment regimens from the PRAMA trial (n = 341) or patients treated at our outpatient clinic (n = 493).

Results

We observed

SUBMITTER: Welsch C 

PROVIDER: S-EPMC5308806 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature